NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Sundia MediTech Company,Ltd. back to previous page show list

Sundia MediTech Company,Ltd.

address: Sundia USA

Address:
9823 Pacific Heights Blvd, Suite F,
San Diego, CA 92121, USA
Tel : +1-858-677-9432
Fax: +1-858-677-0240
Email: info_us@sundia.com
contact: Sundia China Headquarters

Address:
332 Edison Rord, Zhangjiang Hightech Park
Shanghai, China 201203
Tel : +86-21-5109-8642
Fax: +86-21-5079-0032
Email: info@sundia.com
key person: Chairman & CEO - Wang Xiaochuan, Ph.D

COO - Tang Ming, Ph.D. MBA

VP, Chemistry - Qi Ming, Ph.D.

Dr. Chen Jiong, VP of Chemistry

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 0

active in China: YES

SFDA approved: NO

Approvals:
GLP: NO
GMP: NO
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: NO
Active Pharmaceutical: YES
R&D: YES
Ingredients: YES
Western Generics: YES
TCM: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: NO
Stability: YES
Batch Release: NO

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: YES

Chemistry-contract manufacture:
Generics: YES
API: YES
Licensed Drugs: NO

test:
R&D: NO
 
Sundia Meditech is a Shanghai based CRO company providing drug discovery & development services to worldwide clients.
Sundia Meditech is founded by a group of veterans of US pharmaceutical and bio-technological industry. The founding team has talent in organic synthesis, medicinal chemistry, drug design and drug discovery, in vitro & in vivo PK research, business management, and legal services. All founders received their doctorate degrees or advanced academic training from universities in the US, and had extensive working and/or management experience there.
Sundia has strong capabilities and impressive track records in providing to global pharmaceutical and bio-technological companies a broad spectrum of integrated services for drug discovery and development, which are at US industrial standard and operated by experienced scientists to ensure tight quality control to fit partners' requirement.
 
Their CRO services include preparation of intermediates and novel templates (g-kg scale), synthesis of novel building blocks (g-kg scale), medicinal ingredients sets (mg-g scale), and specially designed focused libraries (10-50 mg for each library member with >90% average purity), parallel library synthesis, SAR development, lead optimization and analytic chemistry (QC and ADME/PK measurements), etc.
Sundia has a high quality alliance resources with experienced professional staff dedicated to offer partners the efficacy in animal model services (tumor, diabetes II, immunity and inflammation, and cardiovascular), and toxicity study services.
 
Sundia's long-term strategy is to use company's expertise in custom synthesis, library production, medicinal chemistry, CADD, pharmacology and the advanced Sundia lead optimization platform to serve pharmaceutical and bio-technological companies. Sundia's lead optimization platform can carry out comprehensive multi-property/activity modeling, optimization and virtual screening to select novel small molecule drug candidates with well-balanced potency and ADME (Absorption, Distribution, Metabolism, Excretion) properties that enables collaborators to develop effective, patentable and safe drugs at much lower cost, less risk and greatly reduced failure rate.
 
To sum up, Sundia provides high quality comprehensive services to fulfill the needs of partners in their drug discovery process such as customer synthesis, library design & production, lead generation, lead optimization, PK/ADME, and early stage candidate profiling.
Management
 
Chairman & CEO - Wang Xiaochuan, Ph.D.
Ph.D. of Chemistry, University of Chicago. Prior to Sundia, was VP of R&D in a Shanghai based CRO company, responsible for new drug development and CRO programs with major pharmaceutical companies from USA, Europe, and Japan. 14 year experience in pharmaceutical of USA. Worked for three American companies and studied over 14 different drug targets at various stages. Successfully applied CADD combined with medicinal chemistry, combinatorial chemistry into lead optimization and drug development. Experienced in all stages of new drug discovery and drug development. Dr. Wang is currently holding the adjunct Professor Position in the Pharmacy Academy, Wuhan University.
 
COO - Tang Ming, Ph.D. MBA
Ph.D. of Chemistry, University of Chicago. MBA of Finance, University of Minnesota. 12-year experience with a multinational company in USA, China, Portugal, and Argentina at senior management positions in areas of planning, manufacturing, PD, IT, and sales/marketing. Founder of a business consulting company to serve foreign investment companies, joint ventures, and domestic companies in China and Asia market.
 
VP, Chemistry - Qi Ming, Ph.D.

Ph.D. of Organic Chemistry, Shanghai Institute of Organic chemistry, Chinese Academy of Sciences. Principal Scientist/Project Manager at Senomyx, Inc. successfully managed molecular discovery projects and led lead optimization teams for GPCR agonists’ program. He designed and synthesized product candidate S336 and made major contribution to S807. Senior Scientist in medicinal and combinatorial chemistry departments at Trega Biosciences, on drug discovery program for diabetes based on melanocortin-4 receptor, developed novel combinatorial libraries of heterocycles. Co-authored 45 research articles,8 patents/applications, and 4 technical reviews.
Dr. Chen Jiong, VP of Chemistry
Ph.D. in organic chemistry, Texas Tech University. Postdoctoral fellow at Oregon State University and Texas A&M University. Staff Scientist at Discovery Partners International, USA, a San Diego based CRO company, having extensive experiences in the area of combinatorial chemistry, medicinal chemistry and custom synthesis, as well as project management. Co-authored 15 research articles and 2 book chapters.
 
Service
 
Chemistry
In Sundia MediTech, they are continuously growing their three divisions in the Chemistry Department: medicinal, synthetic and process chemistry. Within their research team, 15% scientists are Ph.D.’s, 49% MS’s, and 36% BS’s.
Their Medicinal Chemistry Division has extensive expertise and successful track records in early stage drug discovery, including hit identification, lead optimization, and Computer Aided Drug Design (CADD). Currently they are offering services in Hit to Lead, SAR Development and Lead Optimization.
 
They also incorporate CADD, Virtual Screening, HTS, PK, ADMET, and PD profile into their medicinal chemistry projects, via collaboration with their strategic partners in Shanghai.

In synthetic chemistry Division, they are providing custom synthesis in all aspects, including intermediates, scaffolds, building blocks, specialty chemicals, medicinal ingredients; diverse or focused library, novel scaffold based diverse library, diverse lib around hit chemical classes, and focused library or analog sets around hits/leads designed based upon PD/ADMET optimization.
Their Process chemistry Division focuses on scale-up, process development and production in large quantities up to multiple Kg’s of key intermediates.
 
CRO Business
Key Characteristics of Sundia High-Tech Service:
Technical Excellence, IP Security, Quick Response and Fair Pricing
Sundia's CRO services include. Preparation of intermediates and novel templates (g-kg scale), synthesis of novel building blocks (g-kg scale), medicinal ingredients sets (mg-g scale), and specially designed focused libraries (10-50 mg for each library member with >90% average purity), parallel library synthesis, SAR development, lead optimization and analytic chemistry (QC and ADME/PK measurements), etc.
Sundia's "Speed-up Engine for Lead Optimization" (SELO) platform can carry out comprehensive multi-property/activity modeling, optimization and virtual screening to select novel small molecule drug candidates with well-balanced potency and ADME (Absorption, Distribution, Metabolism, Excretion) properties.
This lead optimization platform is unique, which integrates synthetic, combinatorial, and medicinal chemistry, high throughput screening, and computer-aided drug design for discovery of small-molecule drugs that enables collaborators to develop effective, patentable and safe drugs at much lower cost, less risk and greatly reduced failure rate.
 
Professional Management:
Internally, they have a strong and experienced management team for a professional delivery channel such as:
- Data Management by using CBIS (Chemical and Biological Information Systems) ,   a commercial package by Chem Innovation   Software Inc., USA
- Weekly Project Review Meeting & Daily Project Progress Meeting
- Project Tracking System
- SOP of Delivery in Customer Service Department
Externally, they keep regular update and timely problem solving approach as followings:
- “No Surprise” communication principle
- Bi-weekly Research Report (or upon customers' request)
- Frequent/regular teleconferences with customers
- Frequent email communications with customer to address the issues and discuss the solutions timely
Sundia team's activities in response to their customers' needs are guided by their management team and facilitated by their administrative and support teams. Advanced technology, high quality of their researchers and scientific excellence lay out a solid foundation to Sundia's high quality of service.
 
Sundia's IP Assurance Enforcement System:
In order to guarantee the IP Safety to their partners, Sundia has established a strict IP Assurance Policy company wide:
- Sundia CDA
- Comprehensive Information System Security Controls
- Professional Management Team with IP protection mindset
- Project Based Lab Practice
- CRO Business Focused
- Supporting Foundation
 

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.